Sitocabnagene Loxiveleucel

N/A

Report date: 2025/05/15 11:45:09

Base Information

Drug NameSitocabnagene Loxiveleucel

Drug Alias NameTAK-007

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > MMLV vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy +[5]

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLupus NephritisLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsLupus Nephritis

Other Information

ATC CodeN/A